Compare · AS vs SILO
AS vs SILO
Side-by-side comparison of Amer Sports Inc. (AS) and Silo Pharma Inc. (SILO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AS and SILO operate in Apparel (Consumer Discretionary), so they compete in similar markets.
- AS is the larger of the two at $16.70B, about 7310.5x SILO ($2.3M).
- Both names hit the wire about 3 times in the past 4 weeks.
- AS has more recent analyst coverage (25 ratings vs 0 for SILO).
- Company
- Amer Sports Inc.
- Silo Pharma Inc.
- Price
- -
- -
- Market cap
- $16.70B
- $2.3M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Apparel
- Apparel
- Exchange
- NYSE
- NASDAQ
- IPO
- 2024
- News (4w)
- 3
- 3
- Recent ratings
- 25
- 0
Latest AS
- SEC Form 6-K filed by Amer Sports Inc.
- Amer Sports, Inc. to Report Third Quarter 2026 Financial Results on November 17, 2026.
- Jefferies initiated coverage on Amer Sports with a new price target
- Chief Strategy Officer Chen Wen-Chang (Victor) exercised 402,495 units of Ordinary Shares at a strike of $7.68 and sold $3,124,040 worth of Ordinary Shares (117,461 units at $26.60), increasing direct ownership by 190% to 434,855 units (SEC Form 4)
- SEC Form 6-K filed by Amer Sports Inc.
- Amer Sports Updates Long-Term Financial Algorithm and Third Quarter 2026 Guidance
- Morgan Stanley resumed coverage on Amer Sports with a new price target
- BTIG Research initiated coverage on Amer Sports with a new price target
- BMO Capital Markets initiated coverage on Amer Sports with a new price target
- Chief Financial Officer Page Andrew E converted options into 4,514 units of Ordinary Shares and sold $57,890 worth of Ordinary Shares (2,022 units at $28.63), increasing direct ownership by 61% to 6,575 units (SEC Form 4) (withholding obligation)
Latest SILO
- SEC Form 8-K filed by Silo Pharma Inc.
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Silo Pharma’s QwikAgents Expands AI Agent Platform with NVIDIA Model Support and New Runtime Flexibility
- Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio
- Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum
- Silo Pharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment
- Silo Pharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Silo Pharma Inc.
- Silo Pharma Granted European Patent Covering Novel PTSD Therapy